Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Members & Subscribers
    • Benefits for CMA Members
    • CPD Credits for Members
    • Subscribe to CMAJ Print
    • Subscription Prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Members & Subscribers
    • Benefits for CMA Members
    • CPD Credits for Members
    • Subscribe to CMAJ Print
    • Subscription Prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Practice

Flumazenil in benzodiazepine overdose

Howard An and Jesse Godwin
CMAJ December 06, 2016 188 (17-18) E537; DOI: https://doi.org/10.1503/cmaj.160357
Howard An
Divisions of Emergency Medicine (Godwin) and Clinical Pharmacology and Toxicology (An, Godwin), Department of Medicine, University of Toronto; Ontario Poison Centre (An, Godwin), Division of Clinical Pharmacology and Toxicology, Hospital for Sick Children, Toronto, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: howard.an@gmail.com
Jesse Godwin
Divisions of Emergency Medicine (Godwin) and Clinical Pharmacology and Toxicology (An, Godwin), Department of Medicine, University of Toronto; Ontario Poison Centre (An, Godwin), Division of Clinical Pharmacology and Toxicology, Hospital for Sick Children, Toronto, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading

Isolated benzodiazepine overdoses are rarely fatal

A population-based retrospective study reported a rate of 3.0–7.9 deaths per million benzodiazepine prescriptions.1 Sedation is common, but severe respiratory depression and hemodynamic instability are rare.2 Supportive care is generally sufficient for the management of benzodiazepine overdose.

Flumazenil antagonizes benzodiazepine activity

Benzodiazepines promote the binding of γ-aminobutyric acid (GABA) to its receptor. The “Z” drugs (zopiclone, zaleplon and zolpidem) act in a similar manner. Flumazenil is a benzodiazepine analogue with minimal intrinsic activity.3 It binds to the extracellular surface of GABAA receptors and competitively displaces benzodiazepine molecules, preventing further benzodiazepine binding.3

Flumazenil should not be used routinely

Flumazenil is contraindicated in patients with unknown or mixed overdose, benzodiazepine tolerance, seizure disorders or a prolonged QRS interval.3 In a recent meta-analysis, serious adverse events were significantly more common among patients with suspected benzodiazepine overdose treated with flumazenil than among those in the placebo group (risk ratio 3.81, 95% confidence interval 1.28–11.39; number needed to harm = 50).2 Seizures and ventricular dysrhythmias can develop, especially if withdrawal is precipitated in benzodiazepine-tolerant individuals or if flumazenil reverses the protective effect of benzodiazepines in patients with unknown or mixed overdose. 3 Seizures may become more difficult to manage and may require the use of propofol or barbiturates. A poison centre should be consulted if the use of flumazenil is being considered.

Select patients may benefit from the administration of flumazenil

Flumazenil can reverse respiratory depression in the rare patient with severe, isolated benzodiazepine or “Z” drug toxicity who does not have contraindications to its use. It is most often considered in accidental pediatric ingestions or reversal of iatrogenic oversedation. Case reports have shown successful flumazenil reversal of paradoxic reactions (agitation) associated with benzodiazepines.4 Flumazenil does not reverse sedation due to barbiturates, ethanol or opioids.

Flumazenil has a short half-life

Evidence regarding optimal dosing is limited. The manufacturer recommends an initial dose of 0.2 mg given over 15 seconds.5 A suggested, more cautious approach would be to administer flumazenil in 0.1-mg doses (or 0.01 mg/kg) each over one minute, to a maximum of 1 mg, or until an effect is achieved or toxicity develops. 2 The half-life of flumazenil is about 50 minutes, which is shorter than that of most benzodiazepines. Therefore, sedation often recurs. Cardiorespiratory monitoring is necessary, and repeat dosing or infusion may be required.5

Footnotes

  • Competing interests: None declared. This article has been peer reviewed.

References

  1. ↵
    1. Buckley NA,
    2. McManus PR
    . Changes in fatalities due to overdose of anxiolytic and sedative drugs in the UK (1983–1999). Drug Saf 2004;27:135–41.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Penninga EI,
    2. Graudal N,
    3. Ladekarl MB,
    4. et al
    . Adverse events associated with flumazenil treatment for the management of suspected benzodiazepine intoxication: a systematic review with meta-analyses of randomised trials. Basic Clin Pharmacol Toxicol 2016;118:37–44.
    OpenUrl
  3. ↵
    1. Sivilotti MLA
    . Flumazenil, naloxone and the ‘coma cocktail’.Br J Clin Pharmacol 2016;81:428–36.
    OpenUrl
  4. ↵
    1. Jackson BF,
    2. Beck LA,
    3. Losek JD
    . Successful flumazenil reversal of paradoxical reaction to midazolam in a child. J Emerg Med 2015;48:e67–72.
    OpenUrl
  5. ↵
    Anexate [package insert]. Basel (Switzerland): Hoffman–La Roche; 2008.
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 188 (17-18)
CMAJ
Vol. 188, Issue 17-18
6 Dec 2016
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Flumazenil in benzodiazepine overdose
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Flumazenil in benzodiazepine overdose
Howard An, Jesse Godwin
CMAJ Dec 2016, 188 (17-18) E537; DOI: 10.1503/cmaj.160357

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Flumazenil in benzodiazepine overdose
Howard An, Jesse Godwin
CMAJ Dec 2016, 188 (17-18) E537; DOI: 10.1503/cmaj.160357
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Isolated benzodiazepine overdoses are rarely fatal
    • Flumazenil antagonizes benzodiazepine activity
    • Flumazenil should not be used routinely
    • Select patients may benefit from the administration of flumazenil
    • Flumazenil has a short half-life
    • Footnotes
    • References
  • Responses
  • Metrics
  • PDF

Related Articles

  • Zopiclone overdose and flumazenil rescue
  • PubMed
  • Google Scholar

Cited By...

  • Zopiclone overdose and flumazenil rescue
  • Google Scholar

More in this TOC Section

  • Duodenal duplication cyst in a 61-year-old man
  • A young woman with fever and polyserositis caused by familial Mediterranean fever
  • Screening for primary aldosteronism in primary care
Show more Practice

Similar Articles

Collections

  • Topics
    • Drugs: adverse reactions
    • Drugs: central nervous system (not psychiatric)
    • Emergency medicine
    • Pharmacology & toxicology

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
  • Accessibiity
  • CMA Civility Standards
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

Powered by HighWire